Following Takeda Pharmaceutical's acquisition of rare disease biotech Shire, the Japanese pharma is divesting its 51.34% majority share of the Chinese biopharma Guangdong Techpool Bio-Pharma to its joint venture partner, Shanghai Pharmaceutical Holding.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,